Download MendeleyNovel ATP competitive MK2 inhibitors with potent biochemical and cell-based activity throughout the series.
Oubrie, A., Kaptein, A., de Zwart, E., Hoogenboom, N., Goorden, R., van de Kar, B., van Hoek, M., de Kimpe, V., van der Heijden, R., Borsboom, J., Kazemier, B., de Roos, J., Scheffers, M., Lommerse, J., Schultz-Fademrecht, C., Barf, T.(2012) Bioorg Med Chem Lett 22: 613-618
- PubMed: 22119462
- DOI: https://doi.org/10.1016/j.bmcl.2011.10.071
- Primary Citation of Related Structures:
3SHE - PubMed Abstract:
Optimization of our previously described pyrrolopiperidone series led to the identification of a new benzamide sub-series, which exhibits consistently high potency in biochemical and cell-based assays throughout the series. Strong inhibition of LPS-induced production of the cytokine TNFα is coupled to the regulation of HSP27 phosphorylation, indicating that the observed cellular effects result from the inhibition of MK2. X-ray crystallographic and computational analyses provide a rationale for the high potency of the series.
Organizational Affiliation:
Merck Research Laboratories, MSD, PO Box 20, 5340 BH Oss, The Netherlands.
